MedTrace Logo

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children

NCT03574389 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 936

Last updated 2024-11-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and immunogenicity of 13-valent Pneumococcal conjugate vaccine in Chinese infant and young children.

Conditions

  • Pneumococcal Infections
  • Pneumococcal Conjugate Vaccine

Interventions

BIOLOGICAL

13vPnC

suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

BIOLOGICAL

Hib

suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
42 Days
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-23
Primary Completion
2021-08-23
Completion
2023-10-13

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03574389 on ClinicalTrials.gov